Beyond conventional approaches: Exploring the collaborative defense of flavonoids and the renin-angiotensin system against Parkinson’s challenges

HTML Full Text

Reference

1. Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9:776847. https://doi.org/10.3389/fpubh.2021.776847
2. Klemann CJHM, Martens GJM, Sharma M, Martens MB, Isacson O, Gasser T, et al. Integrated molecular landscape of Parkinson's disease. Parkinsons Dis. 2017;3(1):14. https://doi.org/10.1038/s41531-017-0015-3
3. Emamzadeh FN, Surguchov A. Parkinson's disease: biomarkers, treatment, and risk factors. Front Neurosci. 2018;12:612. https://doi.org/10.3389/fnins.2018.00612
4. Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795-808. https://doi.org/10.1136/jnnp-2019-322338
5. Alves Da Rocha PA, Mcclelland J, Morris ME. Complementary physical therapies for movement disorders in Parkinson's disease: a systematic review. Eur J PhysRehabil Med. 2015;51(6):693-704.
6. Perez-Lloret S, Otero-Losada M, Toblli JE, Capani F. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease. Expert OpinInvestig Drugs. 2017;26(10):1163-73. https://doi.org/10.1080/13543784.2017.1371133
7. Yang J, Gao Y, Duan Q, Qiu Y, Feng S, Zhan C, et al. Renin-angiotensin system blockers affect cognitive decline in Parkinson's disease: the PPMI dataset. Parkinsonism RelatDisord. 2022;105:90-5. https://doi.org/10.1016/j.parkreldis.2022.10.019
8. Goldstein B, Speth RC, Trivedi M. Renin-angiotensin system gene expression and neurodegenerative diseases. J Renin Angiotensin Aldosterone Syst. 2016;17(3):1470320316666750. https://doi.org/10.1177/1470320316666750
9. Farag E, Sessler DI, Ebrahim Z, Kurz A, Morgan J, Ahuja S, et al. The renin angiotensin system and the brain: new developments. J ClinNeurosci. 2017;46:1-8. https://doi.org/10.1016/j.jocn.2017.08.055
10. Jung UJ, Kim SR. Beneficial effects of flavonoids against Parkinson's disease. J Med Food. 2018;21(5):421-32. https://doi.org/10.1089/jmf.2017.4078
11. Magalingam KB, Radhakrishnan AK, Haleagrahara N. Protective mechanisms of flavonoids in Parkinson's disease. Oxid Med Cell Longev. 2015;2015:314560. https://doi.org/10.1155/2015/314560
12. Tamtaji OR, Hadinezhad T, Fallah M, Shahmirzadi AR, Taghizadeh M, Behnam M, et al. The therapeutic potential of quercetin in Parkinson's disease: insights into its molecular and cellular regulation. Curr Drug Targets. 2020;21(5):509-18. https://doi.org/10.2174/1389450120666191112155654
13. Zhang X, Molsberry SA, Yeh TS, Cassidy A, Schwarzschild MA, Ascherio A, et al. Intake of flavonoids and flavonoid-rich foods and mortality risk among individuals with Parkinson disease: a prospective cohort study. Neurology. 2022;98(10):e1064-76. https://doi.org/10.1212/WNL.0000000000013275
14. Bellavite P. Neuroprotective potentials of flavonoids: experimental studies and mechanisms of action. Antioxidants (Basel). 2023;12(2):280. https://doi.org/10.3390/antiox12020280
15. Prusty SK, Sahu PK, Subudhi BB. Angiotensin mediated oxidative stress and neuroprotective potential of antioxidants and AT1 receptor blockers. Mini Rev Med Chem. 2017;17(6):518-28. https://doi.org/10.2174/1389557516666161025094539
16. Labandeira Garcia JL, Rodríguez Perez AI, Garrido Gil P, Rodriguez Pallares J, Lanciego JL, Guerra MJ. Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration. Front Aging Neurosci. 2017;9:129. https://doi.org/10.3389/fnagi.2017.00129
17. Shinohara K, Liu X, Morgan DA, Davis DR, Sequeira-Lopez MLS, Cassell MD, et al. Selective deletion of the brain-specific isoform of renin causes neurogenic hypertension. Hypertension. 2016;68(6):1385-92. https://doi.org/10.1161/HYPERTENSIONAHA.116.08242
18. Wright JW, Kawas LH, Harding JW. A role for the brain RAS in Alzheimer's and Parkinson's diseases. Front Endocrinol (Lausanne). 2013;4:158. https://doi.org/10.3389/fendo.2013.00158
19. van Thiel BS, Góes Martini A, TeRiet L, Severs D, Uijl E, Garrelds IM, et al. Brain renin-angiotensin system: does it exist?: does? Hypertension. 2017;69(6):1136-44. https://doi.org/10.1161/HYPERTENSIONAHA.116.08922
20. Nakagawa P, Sigmund CD. How is the brain renin-angiotensin system regulated? Hypertension. 2017;70(1):10-8. https://doi.org/10.1161/HYPERTENSIONAHA.117.08550
21. Bodiga VL, Bodiga S. Renin angiotensin system in cognitive function and dementia. Asian J Neurosci. 2013;2013:1-18. https://doi.org/10.1155/2013/102602
22. Rygiel K. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? an overview of research evidence in the elderly patient population. J Postgrad Med. 2016;62(4):242-8. https://doi.org/10.4103/0022-3859.188553
23. Jiang T, Gao L, Lu J, Zhang YD. ACE2-Ang-(1-7)-Mas Axis in Brain: a potential target for prevention and treatment of ischemic stroke. CurrNeuropharmacol. 2013;11:209-17. https://doi.org/10.2174/1570159X11311020007. https://doi.org/10.2174/1570159X11311020007
24. Agassandian K, Grobe JL, Liu X, Agassandian M, Thompson AP, Sigmund CD, et al. Evidence for intraventricular secretion of angiotensinogen and angiotensin by the subfornical organ using transgenic mice. Am J Physiol Regul Integr Comp Physiol. 2017;312:R973-81. doi: https://doi.org/10.1152/ajpregu.00511.2016 https://doi.org/10.1152/ajpregu.00511.2016
25. Uijl E, Ren L, Danser AHJ. Angiotensin generation in the brain: a re-evaluation. Clin Sci (Lond.). 2018;132(8):839-50. https://doi.org/10.1042/CS20180236
26. Mascolo A, Sessa M, Scavone C, De Angelis A, Vitale C, Berrino L, et al. New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): focus on cardiovascular and neurological diseases. Int J Cardiol. 2017;227:734-742. https://doi.org/10.1016/j.ijcard.2016.10.069
27. Miners JS, van Helmond Z, Raiker M, Love S, Kehoe PG. ACE variants and association with brain Aβ levels in Alzheimer's disease. Am J Transl Res. 2010;3(1):73-80.
28. Su G, Dou H, Zhao L, Wang H, Liu G, Huang B, et al. The angiotensin-converting enzyme (ACE) I/D polymorphism in Parkinson's disease. J Renin Angiotensin Aldosterone Syst. 2015;16(2):428-33. https://doi.org/10.1177/1470320313494432
29. Grobe JL, Xu D, Sigmund CD. An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy. Physiology (Bethesda). 2008;23(4):187-93. https://doi.org/10.1152/physiol.00002.2008
30. Shinohara K, Nakagawa P, Gomez J, Morgan DA, Littlejohn NK, Folchert MD, et al. Selective deletion of renin-b in the brain alters drinking and metabolism. Hypertension. 2017;70(5):990-7. https://doi.org/10.1161/HYPERTENSIONAHA.117.09923
31. Ohishi M, Yamamoto K, Rakugi H. Angiotensin (1-7) and other angiotensin peptides. Curr Pharm Des. 2013;19(17):3060-4. https://doi.org/10.2174/1381612811319170013
32. Kamel AS, Abdelkader NF, Abd El-Rahman SS, Emara M, Zaki HF, Khattab MM. Stimulation of ACE2/ANG (1-7)/mas axis by diminazene ameliorates Alzheimer's disease in the D-galactose-ovariectomized rat model: role of PI3K/Akt pathway. MolNeurobiol. 2018;55(10):8188-202. https://doi.org/10.1007/s12035-018-0966-3
33. Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J PhysiolRegulIntegr Comp Physiol. 2007;292(1):R373-81. https://doi.org/10.1152/ajpregu.00292.2006
34. Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: an update. Saudi J Biol Sci. 2020;27(3):905-12. https://doi.org/10.1016/j.sjbs.2020.01.026
35. Ren L, Lu X, Danser AHJ. Revisiting the brain renin-angiotensin system-focus on novel therapies. CurrHypertens Rep. 2019;21(4):28. https://doi.org/10.1007/s11906-019-0937-8
36. Rodriguez Perez AI, Garrido Gil P, Pedrosa MA, Garcia-Garrote M, Valenzuela R, Navarro G, et al. Angiotensin Type 2 receptors: role in aging and neuroinflammation in the SubstantiaNigra. Brain Behav Immun. 2020;87:256-71. https://doi.org/10.1016/j.bbi.2019.12.011
37. Guo S, Som AT, Arai K, Lo EH, Guo S, Som AT, et al. Effects of angiotensin-II on brain endothelial cell permeability via PPARalpha regulation of para-and trans-cellular pathways. Brain Res. 2019;1722:146353. https://doi.org/10.1016/j.brainres.2019.146353
38. Mertens B, Vanderheyden P, Michotte Y, Sarre S. The role of the central renin-angiotensin system in Parkinson's disease. J Renin Angiotensin Aldosterone Syst. 2010;11(1):49-56. https://doi.org/10.1177/1470320309347789
39. Labandeira-Garcia JL, Rodriguez-Pallares J, Rodríguez-Perez AI, Garrido-Gil P, Villar-Cheda B, Valenzuela R, et al. Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease. Am J Neurodegener Dis. 2012;1(3):226-44.
40. Sonsalla PK, Coleman C, Wong LY, Harris SL, Richardson JR, Gadad BS, et al. The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. Exp Neurol. 2013;250:376-83. https://doi.org/10.1016/j.expneurol.2013.10.014
41. Kaur P, Muthuraman A, Kaur M. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives. ACS ChemNeurosci. 2015;6(4):508-21. https://doi.org/10.1021/cn500363g
42. Mogi M, Horiuchi M. Effect of angiotensin II Type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases. GeriatrGerontol Int. 2013;13(1):13-8. https://doi.org/10.1111/j.1447-0594.2012.00900.x
43. De Bundel D, Smolders I, Yang R, Albiston AL, Michotte Y, Chai SY. Angiotensin IV and LVV-Haemorphin 7 enhance spatial working memory in rats: effects on hippocampal glucose levels and blood flow. Neurobiol Learn Mem. 2009;92(1):19-26. https://doi.org/10.1016/j.nlm.2009.02.004
44. Lee J, Albiston AL, Allen AM, Mendelsohn FAO, Ping SE, Barrett GL, et al. Effect of I.C.V. Injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-Hemorphin 7, on spatial learning in rats. Neuroscience. 2004;124(2):341-9. https://doi.org/10.1016/j.neuroscience.2003.12.006
45. Rivas-Santisteban R, Lillo J, Muñoz A, Rodríguez-Pérez AI, Labandeira-García JL, Navarro G, et al. Novel interactions involving the mas receptor show potential of the renin-angiotensin system in the regulation of microglia activation: altered expression in parkinsonism and dyskinesia. Neurotherapeutics. 2021;18(2):998-1016. https://doi.org/10.1007/s13311-020-00986-4
46. Rabie MA, Abd El Fattah MA, Nassar NN, Abdallah DM, El-Abhar HS. The mas receptor as a future perspective in Parkinson's disease. J Neurol Neuromedicine. 2018;3(4):65-8. https://doi.org/10.29245/2572.942X/2018/4.1208
47. de Morais SDB, Shanks J, Zucker IH. Integrative physiological aspects of brain RAS in hypertension. CurrHypertens Rep. 2018;20(2):10. https://doi.org/10.1007/s11906-018-0810-1
48. Tota S, Nath C, Najmi AK, Shukla R, Hanif K. Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memory impairment in mice: role of cholinergic neurotransmission, cerebral blood flow and brain energy metabolism. Behav Brain Res. 2012;232(1):66-76. https://doi.org/10.1016/j.bbr.2012.03.015
49. Solleiro Villavicencio H, Rivas Arancibia S. Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4+T cells in neurodegenerative diseases. Front Cell Neurosci. 2018;12:114. https://doi.org/10.3389/fncel.2018.00114
50. Chen M, Lai L, Li X, Zhang X, He X, Liu W, et al. Baicalein attenuates neurological deficits and preserves blood-brain barrier integrity in a rat model of intracerebralhemorrhage. Neurochem Res. 2016;41(11):3095-102. https://doi.org/10.1007/s11064-016-2032-8
51. Carvalho C, Moreira PI. Oxidative stress: a major player in cerebrovascular alterations associated to neurodegenerative events. Front Physiol. 2018;9:806. https://doi.org/10.3389/fphys.2018.00806
52. Sun MS, Jin H, Sun X, Huang S, Zhang FL, Guo ZN, et al. Free radical damage in ischemia-reperfusion injury: an obstacle in acute ischemic stroke after revascularization therapy. Oxid Med Cell Longev. 2018;2018:3804979. https://doi.org/10.1155/2018/3804979
53. Rodriguez-Perez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, et al. Angiotensin type 1 receptor antagonists protect against alpha-synuclein-induced neuroinflammation and dopaminergic neuron death. Neurotherapeutics. 2018;15(4):1063-81. https://doi.org/10.1007/s13311-018-0646-z
54. Torika N, Asraf K, Roasso E, Danon A, Fleisher-Berkovich S. Angiotensin converting enzyme inhibitors ameliorate brain inflammation associated with microglial activation: possible implications for Alzheimer's disease. J NeuroimmunePharmacol. 2016;11(4):774-85. https://doi.org/10.1007/s11481-016-9703-8
55. Zhao HR, Jiang T, Tian YY, Gao Q, Li Z, Pan Y, et al. Angiotensin II triggers apoptosis via enhancement of NADPH oxidase-dependent oxidative stress in a dopaminergic neuronal cell line. Neurochem Res. 2015;40(4):854-63. https://doi.org/10.1007/s11064-015-1536-y
56. Kim MS, Lee GH, Kim YM, Lee BW, Nam HY, Sim UC, et al. Angiotensin II causes apoptosis of adult hippocampal neural stem cells and memory impairment through the action on AMPK-PGC1α signaling in heart failure. Stem Cells Transl Med. 2017;6(6):1491-503. https://doi.org/10.1002/sctm.16-0382
57. Gao Q, Ou Z, Jiang T, Tian YY, Zhou JS, Wu L, et al. Azilsartan ameliorates apoptosis of dopaminergic neurons and rescues characteristic ParkinsonianBehaviors in a rat model of Parkinson's disease. Oncotarget. 2017;8(15):24099-109. https://doi.org/10.18632/oncotarget.15732
58. Ou Z, Jiang T, Gao Q, Tian YY, Zhou JS, Wu L, et al. Mitochondrial-dependent mechanisms are involved in angiotensin II-induced apoptosis in dopaminergic neurons. J Renin Angiotensin Aldosterone Syst. 2016;17(4):1470320316672349. https://doi.org/10.1177/1470320316672349
59. Auladell C, de Lemos L, Verdaguer E, Ettcheto M, Busquets O, Lazarowski A, et al. Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. Front Biosci (Landmark Ed). 2017;22(5):795-814. https://doi.org/10.2741/4517
60. Ledda F, Paratcha G. Assembly of neuronal connectivity by neurotrophic factors and leucine-rich repeat proteins. Front Cell Neurosci. 2016;10:199. https://doi.org/10.3389/fncel.2016.00199
61. Sampaio TB, Savall AS, Gutierrez MEZ, Pinton S. Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy. Neural Regen Res. 2017;12(4):549-57. https://doi.org/10.4103/1673-5374.205084
62. Ibáñez CF, Andressoo JO. Biology of GDNF and its receptors-relevance for disorders of the central nervous system. Neurobiol Dis. 2017;97(B):80-9. https://doi.org/10.1016/j.nbd.2016.01.021
63. Lindahl M, Saarma M, Lindholm P. Unconventional neurotrophic factors CDNF and MANF: structure, physiological functions and therapeutic potential. Neurobiol Dis. 2017;97(B):90-102. https://doi.org/10.1016/j.nbd.2016.07.009
64. Jackson L, Eldahshan W, Fagan SC, Ergul A. Within the brain: the renin angiotensin system. Int J Mol Sci. 2018;19(3):876. https://doi.org/10.3390/ijms19030876
65. Schaich CL, Wellman TL, Koi B, Erdos B. BDNF acting in the hypothalamus induces acute pressor responses under permissive control of angiotensin II. AutonNeurosci. 2016;197:1-8. https://doi.org/10.1016/j.autneu.2016.02.011
66. Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98(3):1627-738. https://doi.org/10.1152/physrev.00038.2017
67. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3(1):17013. https://doi.org/10.1038/nrdp.2017.13
68. Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. ProgNeurobiol. 2015;125:26-46. https://doi.org/10.1016/j.pneurobio.2014.11.004
69. Rodriguez-Perez AI, Borrajo A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Interaction between NADPH-oxidase and rho-kinase in angiotensin II-induced microglial activation. Glia. 2015;63(3):466-82. https://doi.org/10.1002/glia.22765
70. Ola MS, Ahmed MM, Abuohashish HM, Al-Rejaie SS, Alhomida AS. Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats. Neurochem Res. 2013;38(8):1572-9. https://doi.org/10.1007/s11064-013-1058-4
71. Lin HC, Tseng YF, Shen AL, Chao JCJ, Hsu CY, Lin HL. Association of angiotensin receptor blockers with incident Parkinson disease in patients with hypertension: a retrospective cohort study. Am J Med. 2022;135(8):1001-7. https://doi.org/10.1016/j.amjmed.2022.04.029
72. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem. 2009;109(2):656-69. https://doi.org/10.1111/j.1471-4159.2009.05999.x
73. Goel R, Bhat SA, Rajasekar N, Hanif K, Nath C, Shukla R. Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: protection by angiotensin converting enzyme inhibition. PharmacolBiochemBehav. 2015;133:132-45. https://doi.org/10.1016/j.pbb.2015.04.002
74. Muñoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, Labandeira-Garcia JL. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology. 2006;51(1):112-20. https://doi.org/10.1016/j.neuropharm.2006.03.004
75. Grammatopoulos TN, Jones SM, Ahmadi FA, Hoover BR, Snell LD, Skoch J, et al. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in SubstantiaNigra. MolNeurodegener. 2007;2(1):1. https://doi.org/10.1186/1750-1326-2-1
76. Zhang TT, Yang L, Jiang JG. Bioactive comparison of main components from unripe fruits of RubusChingii Hu and identification of the effective component. Food Funct. 2015;6(7):2205-14. https://doi.org/10.1039/C5FO00406C
77. Hong F, Ming L, Yi S, Zhanxia L, Yongquan W, Chi L. The antihypertensive effect of peptides: a novel alternative to drugs? Peptides. 2008;29(6):1062-71. https://doi.org/10.1016/j.peptides.2008.02.005
78. Farzamirad V, Aluko RE. Angiotensin-converting enzyme inhibition and free-radical scavenging properties of cationic peptides derived from soybean protein hydrolysates. Int J Food SciNutr. 2008;59(5):428-37. https://doi.org/10.1080/09637480701592897
79. Guang C, Phillips RD. Plant food-derived angiotensin I converting enzyme inhibitory peptides. J Agric Food Chem. 2009;57(12):5113-20. https://doi.org/10.1021/jf900494d
80. Loizzo MR, Said A, Tundis R, Rashed K, Statti GA, Hufner A, et al. Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from Ailanthus excelsa (Roxb) (Simaroubaceae). Phytother Res. 2007;21(1):32-6. https://doi.org/10.1002/ptr.2008
81. Margalef M, Bravo FI, Arola-Arnal A, Muguerza B. Natural angiotensin converting enzyme (ACE) inhibitors with antihypertensive properties. In: Andrade PB, Valentão P, Pereira DM. editors. Natural products targeting clinically relevant enzymes. Hoboken, NJ: John Wiley & Sons; 2017. pp. 45-67. Available from: https://onlinelibrary.wiley.com/doi/10.1002/9783527805921.ch3 https://doi.org/10.1002/9783527805921.ch3
82. NileekaBalasuriya BW, Vasantha Rupasinghe HP. Plant flavonoids as angiotensin converting enzyme inhibitors in regulation of hypertension. Funct Foods Health Dis. 2011;1(5):172-88. https://doi.org/10.31989/ffhd.v1i5.132
83. Zilli AMH, Zilli EM. Review of evidence and perspectives of flavonoids on metabolic syndrome and neurodegenerative disease. Protein PeptLett. 2021;28(7):725-34. https://doi.org/10.2174/0929866528666210127152359
84. Zheng W, Tian E, Liu Z, Zhou C, Yang P, Tian K, et al. Small molecule angiotensin converting enzyme inhibitors: a medicinal chemistry perspective. Front Pharmacol. 2022;13:968104. https://doi.org/10.3389/fphar.2022.968104
85. Vallée A, Lecarpentier Y, Guillevin R, Vallée JN. Circadian rhythms, neuroinflammation and oxidative stress in the story of Parkinson's disease. Cells. 2020;9(2):314. https://doi.org/10.3390/cells9020314
86. Wijesekara I, Kim SK. Angiotensin-I-converting enzyme (ACE) inhibitors from marine resources: prospects in the pharmaceutical industry. Mar Drugs. 2010;8(4):1080-93. https://doi.org/10.3390/md8041080
87. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J ClinNutr. 2004;79(5):727-47. https://doi.org/10.1093/ajcn/79.5.727
88. Aherne SA, O'Brien NM. Dietary flavonols: chemistry, food content, and metabolism. Nutrition. 2002;18(1):75-81. https://doi.org/10.1016/S0899-9007(01)00695-5
89. Dias MC, Pinto DCGA, Silva AMS. Plant flavonoids: chemical characteristics and biological activity. Molecules. 2021;26(17):5377. https://doi.org/10.3390/molecules26175377
90. Shen N, Wang T, Gan Q, Liu S, Wang L, Jin B. Plant flavonoids: classification, distribution, biosynthesis, and antioxidant activity. Food Chem. 2022;383:132531. https://doi.org/10.1016/j.foodchem.2022.132531
91. Medina dos Santos N, Berilli Batista P, Batista ÂG, MarósticaJúnior MR. Current evidence on cognitive improvement and neuroprotection promoted by anthocyanins. CurrOpin Food Sci. 2019;26:71-8. https://doi.org/10.1016/j.cofs.2019.03.008
92. Li P, Feng D, Yang D, Li X, Sun J, Wang G, et al. Protective effects of anthocyanins on neurodegenerative diseases. Trends Food Sci Technol. 2021;117:205-17. https://doi.org/10.1016/j.tifs.2021.05.005
93. Caruso G, Torrisi SA, Mogavero MP, Currenti W, Castellano S, Godos J, et al. Polyphenols and neuroprotection: therapeutic implications for cognitive decline. Pharmacol. Ther. 2022;232 (108013):108013. doi: https://doi.org/10.1016/j.pharmthera.2021.108013 https://doi.org/10.1016/j.pharmthera.2021.108013
94. Socci V, Tempesta D, Desideri G, De Gennaro L, Ferrara M. Enhancing human cognition with cocoa flavonoids. Front Nutr. 2017;4:19. https://doi.org/10.3389/fnut.2017.00019
95. Khalatbary AR, Khademi E. The green tea Polyphenolic Catechin Epigallocatechin Gallate and neuro protection. Nutr Neuro sci. 2020;23(4):281-94. https://doi.org/10.1080/1028415X.2018.1500124
96. Singh NA, Mandal AKA, Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J. 2016;15(1):60. https://doi.org/10.1186/s12937-016-0179-4
97. Yao C, Zhang J, Liu G, Chen F, Lin Y. Neuroprotection by (-)-epigallocatechin-3-gallate in a rat model of stroke is mediated through inhibition of endoplasmic reticulum stress. Mol Med Rep. 2014;9(1):69-76. https://doi.org/10.3892/mmr.2013.1778
98. Grewal AK, Singh TG, Sharma D, Sharma V, Singh M, Rahman MH, et al. Mechanistic insights and perspectives involved in neuroprotective action of quercetin. Biomed Pharmacother. 2021;140:111729. https://doi.org/10.1016/j.biopha.2021.111729
99. Dajas F, Abin-Carriquiry JA, Arredondo F, Blasina F, Echeverry C, Martínez M, et al. Quercetin in brain diseases: potential and limits. Neurochem Int. 2015;89:140-8. https://doi.org/10.1016/j.neuint.2015.07.002
100. Boyina HK, Geethakhrishnan SL, Panuganti S, Gangarapu K, Devarakonda KP, Bakshi V, et al. In silico and in vivo studies on quercetin as potential anti-Parkinson agent. Adv Exp Med Biol. 2020;1195:1-11. https://doi.org/10.1007/978-3-030-32633-3_1
101. Pan X, Liu X, Zhao H, Wu B, Liu G. Antioxidant, anti-inflammatory and neuroprotective effect of kaempferol on rotenone-induced Parkinson's disease model of rats and SH-S5Y5 cells by preventing loss of tyrosine hydroxylase. J Funct Foods. 2020;74:104-40. https://doi.org/10.1016/j.jff.2020.104140
102. Han X, Zhao S, Song H, Xu T, Fang Q, Hu G, et al. Kaempferol alleviates LD-mitochondrial damage by promoting autophagy: implications in Parkinson's disease. Redox Biol. 2021;41:(101911). https://doi.org/10.1016/j.redox.2021.101911
103. Dhanraj V, Karuppaiah J, Balakrishnan R, Elangovan N. Myricetin attenuates neurodegeneration and cognitive impairment in parkinsonism. Front Biosci (Elite Ed). 2018;10(3):481-94. https://doi.org/10.2741/e835
104. Wu HC, Hu QL, Zhang SJ, Wang YM, Jin ZK, Lv LF, et al. Neuroprotective effects of genistein on SH-SY5Y cells overexpressing A53T mutant α-synuclein. Neural Regen Res. 2018;13(8):1375-83. https://doi.org/10.4103/1673-5374.235250
105. Siddique YH, Naz F, Jyoti S, Ali F, Rahul. Effect of genistein on the transgenic drosophila model of Parkinson's disease. J Diet Suppl. 2019;16(5):550-63. https://doi.org/10.1080/19390211.2018.1472706
106. Arbabi E, Hamidi G, Talaei SA, Salami M. Estrogen agonist genistein differentially influences the cognitive and motor disorders in an ovariectomized animal model of parkinsonism. Iran J Basic Med Sci. 2016;19(12):1285-90.
107. Wu Q, Wang M, Chen W, Wang K, Wang Y, Exerts D. Daidzein exerts Neuroprotective activity against MPTP-induced Parkinson's disease in experimental mice and lipopolysaccharide-induced BV2 microglial cells. J BiochemMolToxicol. 2022;36(2):e22949. https://doi.org/10.1002/jbt.22949
108. Goel R, Chaudhary R. Effect of daidzein on Parkinson disease induced by reserpine in rats. Braz J Pharm Sci. 2020;56:e18388. https://doi.org/10.1590/s2175-97902019000318388
109. de Rus Jacquet A, Ambaw A, Tambe MA, Ma SY, Timmers M, Grace MH, et al. Neuroprotective mechanisms of red clover and soy isoflavones in Parkinson's disease models. Food Funct. 2021;12(23):11987-2007. https://doi.org/10.1039/D1FO00007A
110. Siddique YH. Role of luteolin in overcoming Parkinson's disease. BioFactors. 2021;47(2):198-206. https://doi.org/10.1002/biof.1706
111. Elmazoglu Z, YarSaglam AS, Sonmez C, Karasu C. Luteolin protects microglia against rotenone-induced toxicity in a hormetic manner through targeting oxidative stress response, genes associated with Parkinson's disease and inflammatory pathways. Drug ChemToxicol. 2020;43(1):96-103. https://doi.org/10.1080/01480545.2018.1504961
112. Chen HQ, Jin ZY, Wang XJ, Xu XM, Deng L, Zhao JW. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. NeurosciLett. 2008;448(2):175-9. https://doi.org/10.1016/j.neulet.2008.10.046
113. Siddique YH, Jyoti S, Naz F. Protective effect of luteolin on the transgenic drosophila model of Parkinson's disease. Braz J Pharm Sci. 2018;54(3):e17760. https://doi.org/10.1590/s2175-97902018000317760
114. Kempuraj D, Thangavel R, Kempuraj DD, Ahmed ME, Selvakumar GP, Raikwar SP, et al. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. BioFactors. 2021;47(2):190-7. https://doi.org/10.1002/biof.1687
115. Warnakulasuriya SN. Antioxidant and cytoprotective properties of long chain fatty acid acylated derivatives of quercetin-3-o-glucoside. Halifax, Canada: Dalhouse University; 2013. https://doi.org/10.3390/biom4040980
116. Ojeda D, Jiménez-Ferrer E, Zamilpa A, Herrera-Arellano A, Tortoriello J, Alvarez L. Inhibition of angiotensin Convertin enzyme (ACE) activity by the AnthocyaninsDelphinidin-and Cyanidin-3-O-Sambubiosides from Hibiscus sabdariffa. J Ethnopharmacol. 2010;127(1):7-10. https://doi.org/10.1016/j.jep.2009.09.059
117. Ma H, Johnson SL, Liu W, DaSilva NA, Meschwitz S, Dain JA, et al. Evaluation of polyphenol anthocyanin-enriched extracts of blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry for free radical scavenging, reactive carbonyl species trapping, anti-glycation, anti-β-amyloid aggregation, and microglial neuroprotective effects. Int J Mol Sci. 2018;19(2):461. https://doi.org/10.3390/ijms19020461
118. Yamane T. Beneficial effects of anthocyanin from natural products on lifestyle-related diseases through inhibition of protease activities. Stud Nat Prod Chem. 2018;58:245-64. https://doi.org/10.1016/B978-0-444-64056-7.00008-8
119. Fernández K, Labra J. Simulated digestion of proanthocyanidins in grape skin and seed extracts and the effects of digestion on the angiotensin I-converting enzyme (ACE) inhibitory activity. Food Chem. 2013;139(1-4):196-202. https://doi.org/10.1016/j.foodchem.2013.01.021
120. Ahmed F, Siddesha JM, Urooj A, Vishwanath BS. Radical scavenging and angiotensin converting enzyme inhibitory activities of standardized extracts of FicusRacemosa stem bark. Phytother Res. 2010;24(12):1839-43. https://doi.org/10.1002/ptr.3205
121. Xu YY, Yang C, Li SN. Effects of genistein on angiotensin-converting enzyme in rats. Life Sci. 2006;79(9):828-37. https://doi.org/10.1016/j.lfs.2006.02.035
122. Montenegro MF, Pessa LR, Tanus-Santos JE. IsoflavoneGenistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin. Eur J Pharmacol. 2009;607(1-3):173-7. https://doi.org/10.1016/j.ejphar.2009.02.015
123. Loizzo M. Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from Ailanthus excelsa (Roxb) (Simaroubaceae). Int J Devoted PharmacolToxicolEval Nat Prod Derivatives. 2007;21:32-6. https://doi.org/10.1002/ptr.2008
124. Chang CI, Chen CC, Wang, SY, Chen JJ, Chen MJ, Wu MD, et al. Two new dimericAbietanoid peroxides with xanthine oxidase and ACE inhibitory activities from the Bark of Cryptomeria Japonica. PhytochemLett. 2020;40:15-20. https://doi.org/10.1016/j.phytol.2020.08.011
125. Salem MA, Michel HE, Ezzat MI, Okba MM, El-Desoky AM, Mohamed SO, et al. Optimization of an extraction solvent for angiotensin-converting enzyme inhibitors from Hibiscus sabdariffa L. based on Its UPLC-MS/MS metabolic profiling. Molecules. 2020;25(10):2307. https://doi.org/10.3390/molecules25102307
126. Loizzo MR, Tundis R, Conforti F, Statti GA, Menichini F. Inhibition of angiotensin converting enzyme activity by five senecio species. Pharm Biol. 2009;47(6):516-20. https://doi.org/10.1080/13880200902845787
127. Tsutsumi Y Shimada A, Miyano A, Nishida T, Mitsunaga T. In vitro screening of angiotensin iconverting enzyme inhibitors from Japanese Cedar (Crptomera Japonica). J Wood Sci. 1997;44(6):463-8. https://doi.org/10.1007/BF00833411
128. Jonadet M, Bastide J, Bastide P, Boyer B, Carnat AP, Lamaison JL. In vitro enzyme inhibitory and in vivo cardioprotective activities of hibiscus (Hibiscus sabdariffa L.). J Pharm Belg. 1990;45(2):120-4.
129. Yonekura Sakakibara K, Higashi Y, Nakabayashi R. The origin and evolution of plant flavonoid metabolism. Front Plant Sci. 2019;10:943. https://doi.org/10.3389/fpls.2019.00943
130. Murota K, Nakamura Y, Uehara M. Flavonoid metabolism: the interaction of metabolites and gut microbiota. Biosci Biotechnol Biochem. 2018;82(4):600-10. https://doi.org/10.1080/09168451.2018.1444467
131. Chen Z, Zheng S, Li L, Jiang H. Metabolism of flavonoids in human: a comprehensive review. Curr Drug Metab. 2014;15(1):48-61. https://doi.org/10.2174/138920021501140218125020
132. Ferri P, Angelino D, Gennari L, Benedetti S, Ambrogini P, Del Grande P, et al. Enhancement of flavonoid ability to cross the blood-brain barrier of rats by co-administration with Alpha-tocopherol. Food Funct. 2015;6:394-400. https://doi.org/10.1039/C4FO00817K

Article Metrics

Similar Articles

Related Search

By author names

Bhadauriya P [PubMed] [Google Scholar ]
Varshney V [PubMed] [Google Scholar ]
A G [PubMed] [Google Scholar ]